You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
迪哲醫藥(688192.SH):2024年淨虧損8.57億元
格隆匯 02-24 15:46

格隆匯2月24日丨迪哲醫藥(688192.SH)公佈2024年度業績快報2024年,公司實現營業收入36,039.45萬元,較上年度增長294.79%。2024年6月,公司第二款核心產品國家1類創新藥高瑞哲(通用名:戈利昔替尼)通過優先審評獲得國家藥監局批準上市,是全球首個且唯一作用於JAK/STAT通路的外周T細胞淋巴瘤(PTCL)新機制治療藥物。依託整體商業化策略和團隊高效執行力以及產品的優異療效,舒沃哲和高瑞哲2024年的銷售實現快速增長。隨着公司收入的大幅增長,2024年公司歸屬於母公司所有者的淨虧損爲85,677.15萬元,較上年度減少25,094.18萬元。公司虧損使得加權平均淨資產收益率、歸屬於母公司的所有者權益及每股淨資產等財務指標出現不同程度的下降。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account